Skip to main content

Table 1 Patients’ characteristics at inclusion

From: Can we safely reduce the administration of 131-iodine in patients with differentiated thyroid cancer? – experience of the Brugmann hospital in Brussels

Parameters Group 1 (%) Group 2 (%) P value
Number of patients 78 (57.4%) 58 (42.6%)
Gender
 - female 63 (80.8%) 42 (72.4%) 0.30
 - male 15 (19,2%) 16 (27.6%)  
Mean ± SD age at diagnosis (years) 50.3 ± 14.25 46.8 ± 15.6 0.42
Histology
 - papillary 62 (79.5%) 44 (75.9%) 0.29
 - papillary follicular variant 6 (7.7%) 6 (10.3%)
 - follicular 10 (12.8%) 8 (13.8%)
TNM classification
 - I 58 (74.4%) 48 (82.7%) 0.38
 - II 4 (5.1%) 5 (8.6%)
 - III 11 (19.0%) 4 (6.9%)
 - IVa 4 (6.9%) 0
 - IVb 0 0
 - IVca 1 (1.3%) 1 (1.7%)
ATA-recurrence risk stratificationb
 - low-risk 33 (42.3%) 18 (31.0%) 0.38
 - intermediate-risk 30 (38.5%) 28 (48.3%)
 - high-risk 15 (19.2%) 12 (20.7%)
Median (range) duration of hospital stay (days) 3 (2–10) 1.5 (1–3) < 0.001
Side effects (n) Constipation (10) 0 < 0.001
Headache (2)
Cervical pain (3)
Response to the therapy
 - complete response 70 (90.9%) 55 (96.5%) 0.20
 - biochemical incomplete response 2 (2.6%) 2 (3.5%)
 - structural incomplete response 3 (3.9%) 0
 - indeterminate response 2 (2.6%) 0
  1. a patients with distant metastases were excluded for the analysis of the results
  2. blow-risk: intrathyroidal DTC, pT1a, clinical N0 or ≤ 5 pathologic N1 micrometastases,M0; intermediate-risk: pT1b, pT2, aggressive histology, minor extrathyroidal extension, vascular invasion, or > 5 involved lymph nodes (0.2–3 cm), M0; high-risk: pT3, pT4, gross extrathyroidal extension, incomplete tumor resection, distant metastases, or lymph node > 3 cm,